Atara Biotherapeutics (ATRA) stock surges as the recent FDA meeting supports a resubmission path for its tab-cel cell therapy ...
InvestorsHub on MSN
FDA resubmission path for Tab-cel keeps Atara’s (ATRA) regulatory timeline alive
Atara Biotherapeutics said the FDA outlined a potential pathway for resubmitting the tabelecleucel application after a recent ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
BENSALEM, Pa., May 1, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit ...
Analysts Estimate Atara Biotherapeutics (ATRA) to Report a Decline in Earnings: What to Look Out for
Atara Biotherapeutics (ATRA) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2022. This widely-known consensus ...
What are the allegations? Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate According to the complaint, during the class ...
This past spring, Congress passed a number of important tax provisions that will impact how taxpayers manage their assets and estates. One of particular significance is the American Tax Relief Act of ...
Please provide your email address to receive an email when new articles are posted on . The addition of all-trans retinoic acid to pembrolizumab conferred benefit to patients with metastatic melanoma, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results